Brief: Neuronetics Receives 510(K) Clearance For Neurostar Advanced Therapy
12/06/2023 15:15
June 12 (Reuters) - Neuronetics Inc STIM.O :
* NEURONETICS RECEIVES 510(K) CLEARANCE FOR OCD MT CAP FOR
NEUROSTAR ADVANCED THERAPY
Source text for Eikon: ID:nGNX4LLKmw
Further company coverage: STIM.O
(reuters.briefs@thomsonreuters.com)
Recent news on Neuronetics
See all newsBrief: Neuronetics And Ant Neuro Announce Strategic Collaboration To Integrate Neuronavigation With Neurostar Tms Treatment
Neuronetics Q1 revenue rises 8%, slightly beats estimates
Brief: Neuronetics Inc - Board Reviews Jorey Chernett Letter And Acknowledges Shareholder Engagement
Brief: Neuronetics Inc Initiates Workforce Reduction Impacting Up To 5% Of Employees
Brief: Neuronetics Announces Chief Financial Officer Transition